(Stroke. 1995;26:1841-1848.)
© 1995 American Heart Association, Inc.
Articles |
Lipoprotein(a) Serum Concentration and Apolipoprotein(a) Phenotype Correlate With Severity and Presence of Ischemic Cerebrovascular Disease
From the Institute for Medical Biochemistry, Karl-Franzens Universität Graz (G.J., W.P., Q.C., J.G.) and Hospital Barmherzige Brüder Eggenberg (P.K.), Graz, Austria; Organon Teknika/Biotechnology Research Institute, Rockville, Md (W.C.T.-P., P.F.M., B.T.B., J.H.R.); and Organon Teknika Corporation, Durham, NC (A.G.S.).
Correspondence to Dr G. Jürgens, Institute for Medical Biochemistry, Karl-Franzens Universität Graz, Harrachg 21, A-8010 Graz, Austria. E-mail juergens@bkfug.kfunigraz.ac.at.
Background and Purpose Serum lipoprotein(a) [Lp(a)] levels are genetically determined and considered to be an independent risk factor for atherosclerosis. The aim of this study was to provide a complete analysis of Lp(a) serum levels, apolipoprotein(a) phenotypes, and other lipid parameters for different forms of severity of symptomatic ischemic cerebrovascular disorders as well as for different stages of carotid atherosclerosis.
Methods Lp(a) concentration, apolipoprotein(a) phenotype, triglyceride, low-density lipoprotein, high-density lipoprotein, and total cholesterol levels of blind-coded specimens as well as degree of carotid artery stenosis were assessed in a consecutive series of patients with ischemic cerebrovascular disease. We evaluated 265 male (34%) and female (66%) patients (mean age, 51±7.4 years) with transient ischemic attack (55.8%), prolonged reversible ischemic neurological deficits (28.3%), and cerebral infarction (15.9%) as well as 288 male (30%) and female (70%) control subjects (mean age, 51±7.1 years). All subjects were white.
Results Lp(a), total, and low-density lipoprotein
cholesterol were statistically significantly elevated in
all patients compared with control subjects. Lp(a) correlated with the
severity of symptomatic cerebrovascular disease and the
degree of carotid stenosis. Logistic regression
analysis revealed Lp(a) as the best single marker for the
presence of cerebrovascular disease (P<.001) followed by
high-density lipoprotein cholesterol
(P=.003) and triglycerides (P=.049).
With a cutoff of 20 mg/dL of Lp(a), the odds ratio for a subject to
have had ischemic stroke with elevated Lp(a) was 20.3 and 23.7
depending on the method of the Lp(a) estimation, whereas the odds ratio
when the sonography score was >0 was 15.4. The investigation of the
distribution of the apo(a) phenotypes revealed that 16.73% of
the control subjects had major isoforms 
580 kD molecular weight (B,
F, S1, S2) versus 42.65% of the patients' group (P<.001).
These isoforms were also present in 14.71% of all individuals with
a sonography score of 0 but in 52.30% of all individuals with a
sonography score >0 (P<.001).
Conclusions This case-control study shows that an elevated Lp(a) level is the primary factor associated with the presence of ischemic cerebrovascular disease and that the increased portion of the smaller-molecular-weight apo(a) isoforms in patients and individuals with a sonography score >0 points toward an inherited predisposition for this disease.
Key Words: apolipoproteins • cerebrovascular disorders • lipoproteins • risk factors
This article has been cited by other articles:
 |
|
 |
|
  H. Jana, L. Vaclav, M. Hynek, C. Zdenek, and T. Vladislav Portal and Mesenteric Vein Thromboses in a Patient With Prothrombin G20210 Mutation, Elevated Lipoprotein (a), and High Factor VIII Clinical and Applied Thrombosis/Hemostasis, October 1, 2008; 14(4): 481 - 485. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Smolders, R. Lemmens, and V. Thijs Lipoprotein (a) and Stroke: A Meta-Analysis of Observational Studies Stroke, June 1, 2007; 38(6): 1959 - 1966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. Jones, A. M. van Rij, J. Cole, M. J.A. Williams, E. H. Bateman, S. M. Marcovina, M. Deng, and S. P.A. McCormick Plasma Lipoprotein(a) Indicates Risk for 4 Distinct Forms of Vascular Disease Clin. Chem., April 1, 2007; 53(4): 679 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ohira, P. J. Schreiner, J. D. Morrisett, L. E. Chambless, W. D. Rosamond, and A. R. Folsom Lipoprotein(a) and Incident Ischemic Stroke: The Atherosclerosis Risk in Communities (ARIC) Study Stroke, June 1, 2006; 37(6): 1407 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zambrelli, E. Emanuele, S. Marcheselli, L. Montagna, D. Geroldi, and G. Micieli Apo(a) size in ischemic stroke: Relation with subtype and severity on hospital admission Neurology, April 26, 2005; 64(8): 1366 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Arenillas, C. A. Molina, P. Chacon, A. Rovira, J. Montaner, P. Coscojuela, E. Sanchez, M. Quintana, and J. Alvarez-Sabin High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis Neurology, July 13, 2004; 63(1): 27 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Iwamoto, S. Fukuda, S. Shimizu, and M. Takasaki Long-Term Effects of Lipoprotein(a) on Carotid Atherosclerosis in Elderly Japanese J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2004; 59(1): M62 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Sun, Z. Li, H. Zhang, A. Ma, Y. Liao, D. Wang, B. Zhao, Z. Zhu, J. Zhao, Z. Zhang, et al. Pentanucleotide TTTTA Repeat Polymorphism of Apolipoprotein(a) Gene and Plasma Lipoprotein(a) Are Associated With Ischemic and Hemorrhagic Stroke in Chinese: A Multicenter Case-Control Study in China Stroke, July 1, 2003; 34(7): 1617 - 1622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Komai, R. Morishita, S. Yamada, M. Oishi, S. Iguchi, M. Aoki, M. Sasaki, I. Sakurabayashi, J. Higaki, and T. Ogihara Mitogenic Activity of Oxidized Lipoprotein (a) on Human Vascular Smooth Muscle Cells Hypertension, September 1, 2002; 40(3): 310 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lochow, A. Schwartzbard, J. Guest, C. Ripps, D. Matalon, R. Gambetta, P. A. Tunick, and S. Sedlis Elevated Prothrombin and Activated Protein C Resistance in Patients with Thoracic Aortic Atheroma Angiology, July 1, 2002; 53(4): 423 - 428. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Paultre, C. H. Tuck, B. Boden-Albala, D. E. Kargman, E. Todd, J. Jones, M. C. Paik, R. L. Sacco, and L. Berglund Relation of Apo(a) Size to Carotid Atherosclerosis in an Elderly Multiethnic Population Arterioscler. Thromb. Vasc. Biol., January 1, 2002; 22(1): 141 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Sarti, L. Pantoni, G. Pracucci, A. Di Carlo, P. Vanni, and D. Inzitari Lipoprotein(a) and Cognitive Performances in an Elderly White Population : Cross-Sectional and Follow-Up Data Stroke, July 1, 2001; 32(7): 1678 - 1683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. von Depka, U. Nowak-Gottl, R. Eisert, C. Dieterich, M. Barthels, I. Scharrer, A. Ganser, and S. Ehrenforth Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism Blood, November 15, 2000; 96(10): 3364 - 3368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yamada, R. Morishita, S. Nakamura, T. Ogihara, Y. Kusumi, I. Sakurai, N. Kubo, and I. Sakurabayashi Development of Antibody Against Epitope of Lipoprotein(a) Modified by Oxidation : Evaluation of New Enzyme-Linked Immunosorbent Assay for Oxidized Lipoprotein(a) Circulation, October 3, 2000; 102(14): 1639 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gunther, R. Junker, R. Strater, R. Schobess, K. Kurnik, A. Kosch, U. Nowak-Gottl, and f. t. C. S. S. Group Symptomatic Ischemic Stroke in Full-Term Neonates : Role of Acquired and Genetic Prothrombotic Risk Factors Stroke, October 1, 2000; 31(10): 2437 - 2441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J Milionis, A. F Winder, and D. P Mikhailidis Lipoprotein (a) and stroke J. Clin. Pathol., July 1, 2000; 53(7): 487 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Dardik, C. D. Schwartzkopf, D. E. Stevens, and R. E. Chatelain A quantitative assay for the non-covalent association between apolipoprotein[a] and apolipoprotein B: an alternative measure of Lp[a] assembly J. Lipid Res., June 1, 2000; 41(6): 1013 - 1019. [Abstract] [Full Text]
|
|
|
|
|
|
R. Morishita, S. Yamada, K. Yamamoto, N. Tomita, I. Kida, I. Sakurabayashi, A. Kikuchi, Y. Kaneda, R. Lawn, J. Higaki, et al. Novel Therapeutic Strategy for Atherosclerosis : Ribozyme Oligonucleotides Against Apolipoprotein(a) Selectively Inhibit Apolipoprotein(a) But Not Plasminogen Gene Expression Circulation, November 3, 1998; 98(18): 1898 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Papadakis, D. P Mikhailidis, and A. F Winder Lipids and stroke: neglect of a useful preventive measure? Cardiovasc Res, November 1, 1998; 40(2): 265 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Morishita, S. Yamada, J. Higaki, N. Tomita, I. Kida, M. Aoki, A. Moriguchi, S.-i. Hayashi, I. Sakurabayashi, Y. Kaneda, et al. Conditioned Medium From HepG2 Cells Transfected With Human Apolipoprotein(a) Gene Stimulates Growth of Human Vascular Smooth Muscle Cells : Effects of Overexpression of Human Apolipoprotein(a) Gene Hypertension, August 1, 1998; 32(2): 215 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Poon, X. Zhang, K. G. Dunsky, M. B. Taubman, and P. C. Harpel Apolipoprotein(a) Induces Monocyte Chemotactic Activity in Human Vascular Endothelial Cells Circulation, October 21, 1997; 96(8): 2514 - 2519. [Abstract] [Full Text]
|
|
|
|
|
|
B. R. Zysow, K. Kauser, R. M. Lawn, and G. M. Rubanyi Effects of Estrus Cycle, Ovariectomy, and Treatment with Estrogen, Tamoxifen, and Progesterone on Apolipoprotein(a) Gene Expression in Transgenic Mice Arterioscler. Thromb. Vasc. Biol., September 1, 1997; 17(9): 1741 - 1745. [Abstract] [Full Text]
|
|
|
|
|
|
A. A.-R. Higazi, E. Lavi, K. Bdeir, A. M. Ulrich, D. G. Jamieson, D. J. Rader, D. C. Usher, W. Kane, T. Ganz, and D. B. Cines Defensin Stimulates the Binding of Lipoprotein (a) to Human Vascular Endothelial and Smooth Muscle Cells Blood, June 15, 1997; 89(12): 4290 - 4298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Lawn, A. D. Pearle, L. L. Kunz, E. M. Rubin, J. Reckless, J. C. Metcalfe, and D. J. Grainger Feedback Mechanism of Focal Vascular Lesion Formation in Transgenic Apolipoprotein(a) Mice J. Biol. Chem., December 6, 1996; 271(49): 31367 - 31371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Huby, C. Dachet, R. M. Lawn, J. Wickings, M. J. Chapman, and J. Thillet Functional Analysis of the Chimpanzee and Human apo(a) Promoter Sequences. IDENTIFICATION OF SEQUENCE VARIATIONS RESPONSIBLE FOR ELEVATED TRANSCRIPTIONAL ACTIVITY IN CHIMPANZEE J. Biol. Chem., June 15, 2001; 276(25): 22209 - 22214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Morishita, M. Sakaki, K. Yamamoto, S. Iguchi, M. Aoki, K. Yamasaki, K. Matsumoto, T. Nakamura, R. Lawn, T. Ogihara, et al. Impairment of Collateral Formation in Lipoprotein(a) Transgenic Mice: Therapeutic Angiogenesis Induced by Human Hepatocyte Growth Factor Gene Circulation, March 26, 2002; 105(12): 1491 - 1496. [Abstract] [Full Text] [PDF]
|
|